

# Roni Shouval

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2311873/publications.pdf>

Version: 2024-02-01

631  
papers

15,231  
citations

26630  
56  
h-index

40979  
93  
g-index

659  
all docs

659  
docs citations

659  
times ranked

13661  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. <i>Haematologica</i> , 2022, 107, 1054-1063.	3.5	20
2	The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT. <i>Blood Advances</i> , 2022, 6, 1525-1535.	5.2	17
3	Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 23-30.	2.4	4
4	ETV6-NCOA2 fusion induces T/myeloid mixed-phenotype leukemia through transformation of nonthymic hematopoietic progenitor cells. <i>Blood</i> , 2022, 139, 399-412.	1.4	10
5	Origins of bloodstream infections following fecal microbiota transplantation: a strain-level analysis. <i>Blood Advances</i> , 2022, 6, 568-573.	5.2	8
6	The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. <i>Bone Marrow Transplantation</i> , 2022, 57, 57-64.	2.4	8
7	Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 31-37.	2.4	4
8	Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients. <i>British Journal of Haematology</i> , 2022, 196, 884-891.	2.5	48
9	Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 215-223.	2.4	36
10	An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2022, 139, 1098-1110.	1.4	46
11	A polygenic risk score for multiple myeloma risk prediction. <i>European Journal of Human Genetics</i> , 2022, 30, 474-479.	2.8	5
12	Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 86.e1-86.e8.	1.2	13
13	Machine learning-based prediction of 1-year mortality for acute coronary syndrome <sup>®</sup> . <i>Journal of Cardiology</i> , 2022, 79, 342-351.	1.9	8
14	ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy. <i>Annals of Hematology</i> , 2022, 101, 309-316.	1.8	4
15	Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 399-406.	2.4	9
16	Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party European society of blood and marrow transplantation. <i>American Journal of Hematology</i> , 2022, 97, 274-282.	4.1	3
17	The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML. <i>Bone Marrow Transplantation</i> , 2022, 57, 384-390.	2.4	10
18	Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia. <i>Cancer Medicine</i> , 2022, 11, 1068-1080.	2.8	7

#	ARTICLE	IF	CITATIONS
19	Evaluating outcomes of adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma treated on the GMALL 07/2003 protocol. <i>Annals of Hematology</i> , 2022, 101, 581-593.	1.8	4
20	20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Cancer Research</i> , 2022, 28, 1004-1012.	7.0	12
21	A randomized phase 3 trial of interferon- $\gamma$ vs hydroxyurea in polycythemia vera and essential thrombocythemia. <i>Blood</i> , 2022, 139, 2931-2941.	1.4	45
22	High-Throughput Imaging of CRISPR- and Recombinant Adeno-Associated Virus-Induced DNA Damage Response in Human Hematopoietic Stem and Progenitor Cells. <i>CRISPR Journal</i> , 2022, 5, 80-94.	2.9	16
23	Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 572-578.	2.4	4
24	Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 369-381.	1.6	60
25	An instructive role for Interleukin-7 receptor $\gamma$ in the development of human B-cell precursor leukemia. <i>Nature Communications</i> , 2022, 13, 659.	12.8	12
26	Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 251-257.	1.2	14
27	Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies. <i>Cells</i> , 2022, 11, 1140.	4.1	8
28	Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis. <i>Bone Marrow Transplantation</i> , 2022, , .	2.4	0
29	Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1334-1342.	1.8	16
30	Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 1116-1123.	2.4	5
31	Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 1260-1268.	2.4	1
32	Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2022, 57, 1269-1276.	2.4	6
33	Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia. <i>Cancer</i> , 2022, 128, 2922-2931.	4.1	17
34	The utility of the novel optimized HLH inflammatory (OHI) index for predicting the risk for mortality and causes of death in lymphoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7570-7570.	1.6	0
35	Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis. <i>Clinical Cancer Research</i> , 2022, 28, 4258-4266.	7.0	15
36	Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia. <i>Haematologica</i> , 2021, 106, 1591-1598.	3.5	29

#	ARTICLE	IF	CITATIONS
37	The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study. Bone Marrow Transplantation, 2021, 56, 20-29.	2.4	1
38	Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2021, 56, 532-535.	2.4	36
39	Multiple Myeloma Presenting in Patients Younger than 50 Years of Age: A Single Institution Experience. Acta Haematologica, 2021, 144, 58-65.	1.4	8
40	Machine learning and artificial intelligence in haematology. British Journal of Haematology, 2021, 192, 239-250.	2.5	64
41	Common gene variants within 3' untranslated regions as modulators of multiple myeloma risk and survival. International Journal of Cancer, 2021, 148, 1887-1894.	5.1	3
42	Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia. Clinical Cancer Research, 2021, 27, 843-851.	7.0	25
43	Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. Bone Marrow Transplantation, 2021, 56, 218-224.	2.4	32
44	Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. Bone Marrow Transplantation, 2021, 56, 622-634.	2.4	9
45	Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT. Bone Marrow Transplantation, 2021, 56, 1077-1085.	2.4	4
46	BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. Cancer, 2021, 127, 1246-1259.	4.1	21
47	Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). Cancer Medicine, 2021, 10, 23-33.	2.8	7
48	Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy, 2021, 27, 171.e1-171.e8.	1.2	9
49	Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. Bone Marrow Transplantation, 2021, 56, 1134-1143.	2.4	17
50	Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation, 2021, 56, 1190-1199.	2.4	16
51	A phase II study of bisantrene in patients with relapsed/refractory acute myeloid leukemia. European Journal of Haematology, 2021, 106, 260-266.	2.2	3
52	Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2021, 56, 1047-1055.	2.4	2
53	Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission. Bone Marrow Transplantation, 2021, 56, 1272-1280.	2.4	18
54	Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation, 2021, 56, 917-927.	2.4	8

#	ARTICLE	IF	CITATIONS
55	Carfilzomib combined with cyclosporine and methotrexate for the prevention of graft-versus-host disease after allogeneic stem-cell transplantation from unrelated donors. Bone Marrow Transplantation, 2021, 56, 451-456.	2.4	0
56	Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2021, 56, 481-491.	2.4	10
57	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 6-20.	1.2	45
58	How we can mitigate the side effects associated with systemic glucocorticoid after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 1248-1256.	2.4	10
59	Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment. Journal of Cancer, 2021, 12, 5423-5431.	2.5	5
60	Primum non nocere: allo-HSCT for AML in CR1. Blood, 2021, 137, 438-439.	1.4	0
61	How Do We Manage Hematopoietic Cell Transplant during the SARS-CoV-2 Pandemic?. Acta Haematologica, 2021, 144, 500-507.	1.4	4
62	Prognostic impact of early "versus" late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT. European Journal of Haematology, 2021, 106, 708-715.	2.2	0
63	Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells. Leukemia and Lymphoma, 2021, 62, 1692-1701.	1.3	22
64	Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma. Blood Advances, 2021, 5, 823-828.	5.2	19
65	The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2021, 27, 233-240.	1.2	24
66	Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT. Bone Marrow Transplantation, 2021, 56, 1842-1849.	2.4	4
67	Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT. Bone Marrow Transplantation, 2021, 56, 1900-1907.	2.4	18
68	Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. Lancet Haematology, the, 2021, 8, e205-e215.	4.6	26
69	Outcome of "cell" "replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer, 2021, 127, 2507-2514.	4.1	8
70	Second allogeneic haematopoietic cell transplantation using HLA "matched unrelated <i>versus</i> " "cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. British Journal of Haematology, 2021, 193, 592-601.	2.5	17
71	Allogeneic haematopoietic cell transplantation for myelofibrosis: a real "life perspective. British Journal of Haematology, 2021, 195, 495-506.	2.5	5
72	Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. Clinical Cancer Research, 2021, 27, 3695-3703.	7.0	7

#	ARTICLE	IF	CITATIONS
73	Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. Bone Marrow Transplantation, 2021, 56, 2194-2202.	2.4	10
74	The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy. British Journal of Haematology, 2021, 193, 1060-1075.	2.5	13
75	Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Journal of Hematology and Oncology, 2021, 14, 53.	17.0	51
76	Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT. Blood Cancer Journal, 2021, 11, 88.	6.2	14
77	Feasibility and Outcomes of a Third Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Transplantation and Cellular Therapy, 2021, 27, 408.e1-408.e6.	1.2	6
78	Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia. Journal of Hematology and Oncology, 2021, 14, 76.	17.0	12
79	Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT. Bone Marrow Transplantation, 2021, 56, 2445-2453.	2.4	6
80	Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT. Journal of Hematology and Oncology, 2021, 14, 84.	17.0	27
81	A novel index using inflammatory markers improves the diagnosis of hemophagocytic lymphohistiocytosis in patients with hematologic malignancies.. Journal of Clinical Oncology, 2021, 39, 7563-7563.	1.6	1
82	Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia. Cancers, 2021, 13, 2699.	3.7	11
83	Complete Remission with Incomplete Blood Count Recovery Is a Strong Predictor of Nonrelapse Mortality in Acute Myeloid Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Acta Haematologica, 2021, 144, 613-619.	1.4	4
84	High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma. Bone Marrow Transplantation, 2021, 56, 2690-2696.	2.4	6
85	Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation. International Journal of Hematology, 2021, 114, 363-372.	1.6	4
86	CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study. Cancer Immunology Research, 2021, 9, 1061-1070.	3.4	37
87	Predictive factors for outcome of first allogeneic transplant for elderly patients with acute lymphoblastic leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 831-840.	0.4	1
88	Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Advances, 2021, 5, 3397-3406.	5.2	59
89	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 642-649.	1.2	65
90	The HPSE Gene Insulatorâ€”A Novel Regulatory Element That Affects Heparanase Expression, Stem Cell Mobilization, and the Risk of Acute Graft versus Host Disease. Cells, 2021, 10, 2523.	4.1	5



#	ARTICLE	IF	CITATIONS
91	Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reducedâ€intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. British Journal of Haematology, 2021, 195, 417-428.	2.5	9
92	Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	3
93	Predicting 30-day mortality after ST elevation myocardial infarction: Machine learning- based random forest and its external validation using two independent nationwide datasets. Journal of Cardiology, 2021, 78, 439-446.	1.9	16
94	Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy. Journal of the American College of Cardiology, 2021, 78, 1800-1813.	2.8	55
95	Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prophylaxis in Alternative Donor Stem Cell Transplantation: Immune Reconstitution and Infection Risk. Transplantation and Cellular Therapy, 2021, 27, 883-884.	1.2	4
96	Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Leukemia, 2021, 35, 3585-3588.	7.2	72
97	Long-Term Outcome of Peripheral Blood Autologous Stem Cell Transplantation (AutoSCT) for De Novo Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Vs Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2021, 138, 1840-1840.	1.4	0
98	Lesion Characteristics and Patterns of Failure in Diffuse Large B Cell Lymphoma Patients Treated with Bridging Radiotherapy Prior to Chimeric Antigen Receptor T Cell Therapy. Blood, 2021, 138, 1429-1429.	1.4	5
99	Novel Agents May be Preferable to Chemotherapy for Large B-Cell Lymphoma Progressing after CD19-CAR-T: A Multicenter Observational Study. Blood, 2021, 138, 883-883.	1.4	7
100	Higher Efficacy of TBI + Cyclophosphamide Than TBI + Fludarabine As Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT. Blood, 2021, 138, 2876-2876.	1.4	1
101	Primary Central Nervous System Involvement at Initial Diagnosis Remains an Independent Risk Factor for Relapse in Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation in CR1. Blood, 2021, 138, 2901-2901.	1.4	0
102	Encouraging Survival and High Rates of Toxicity: Allogeneic Hematopoietic Cell Transplantation after Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Aggressive Lymphoma Patients. Blood, 2021, 138, 910-910.	1.4	1
103	KIR-HLA Interactions Lack Clinical Utility in Matched Unrelated Donor Transplantation for AML: An Analysis of the CIBMTR and DRST Registries. Blood, 2021, 138, 419-419.	1.4	1
104	Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Blood, 2021, 138, 2818-2818.	1.4	0
105	ELN 2017 Classification Significantly Impacts on the Risk of Early Death in Acute Myeloid Leukemia Patients Receiving Intensive Induction Chemotherapy. Blood, 2021, 138, 3392-3392.	1.4	0
106	Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy. Blood, 2021, 138, 3390-3390.	1.4	0
107	Five-Year Experience Using Bridging Radiotherapy Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapies for B-Cell Malignancies at Memorial Sloan Kettering Cancer Center. Blood, 2021, 138, 2507-2507.	1.4	1
108	Allogeneic Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia (AML) in Second Complete Remission (CR2) Transplanted from Unrelated Donors with Post Transplant Cyclophosphamide (PTCy). a Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Blood, 2021, 138, 3916-3916.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Isocitrate Dehydrogenase (IDH) 1 and 2 Mutation Is an Independent Predictor of Better Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Study of the ALWP of EBMT. <i>Blood</i> , 2021, 138, 2920-2920.	1.4	1
110	Venetoclax Reverses Metabolic Reprogramming Induced By S1P Modulator FTY720, Suppresses Oxidative Phosphorylation and Synergistically Targets Multiple Myeloma. <i>Blood</i> , 2021, 138, 1195-1195.	1.4	0
111	TP53 and CD19-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 710-710.	1.4	1
112	CMV Seropositive Status Increases Heparanase SNPs Regulatory Activity, Risk of Acute GVHD and Yield of CD34+ Cell Mobilization. <i>Cells</i> , 2021, 10, 3489.	4.1	2
113	Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. <i>Haematologica</i> , 2020, 105, 193-200.	3.5	29
114	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. <i>Bone Marrow Transplantation</i> , 2020, 55, 485-495.	2.4	61
115	Fludarabine/busulfan versus fludarabine/total-body-irradiation (2â€‰%Gy) as conditioning prior to allogeneic stem cell transplantation in patients (â‰¥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT. <i>Bone Marrow Transplantation</i> , 2020, 55, 729-739.	2.4	4
116	Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose?. <i>Bone Marrow Transplantation</i> , 2020, 55, 505-522.	2.4	19
117	Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT. <i>Leukemia</i> , 2020, 34, 283-292.	7.2	48
118	Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. <i>Leukemia</i> , 2020, 34, 87-99.	7.2	25
119	Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. <i>Bone Marrow Transplantation</i> , 2020, 55, 126-136.	2.4	196
120	Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepea conditioning is associated with favorable outcomes in myelofibrosis. <i>Bone Marrow Transplantation</i> , 2020, 55, 147-156.	2.4	10
121	Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study. <i>Leukemia</i> , 2020, 34, 128-137.	7.2	36
122	Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. <i>American Journal of Hematology</i> , 2020, 95, 151-155.	4.1	43
123	The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2020, 34, 1144-1153.	7.2	12
124	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Bone Marrow Transplantation</i> , 2020, 55, 681-694.	2.4	39
125	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 936-942.	2.0	15
126	Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia. <i>Current Research in Translational Medicine</i> , 2020, 68, 17-22.	1.8	24



#	ARTICLE	IF	CITATIONS
127	Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS study. American Journal of Hematology, 2020, 95, 362-371.	4.1	102
128	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica, 2020, 105, 297-316.	3.5	230
129	Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Cancer, 2020, 126, 1004-1015.	4.1	14
130	Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years. Clinical Cancer Research, 2020, 26, 6475-6482.	7.0	40
131	Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e947-e955.	0.4	4
132	Patterns of salivary microbiota injury and oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation. Blood Advances, 2020, 4, 2912-2917.	5.2	39
133	Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1915-1922.	2.0	24
134	Progression of disease within 24 months of initial therapy (POD24) detected incidentally in imaging does not necessarily indicate worse outcome. Leukemia and Lymphoma, 2020, 61, 2645-2651.	1.3	3
135	Impact of total body irradiation vs chemotherapy-based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia. American Journal of Hematology, 2020, 95, 1200-1208.	4.1	14
136	Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response. Journal of Hematology and Oncology, 2020, 13, 158.	17.0	24
137	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Advances, 2020, 4, 3180-3190.	5.2	18
138	FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 2165-2173.	2.0	17
139	Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. Bone Marrow Transplantation, 2020, 55, 2244-2253.	2.4	6
140	Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. Journal of Hematology and Oncology, 2020, 13, 46.	17.0	68
141	Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study. Journal of Hematology and Oncology, 2020, 13, 42.	17.0	56
142	Resveratrol Enhances mRNA and siRNA Lipid Nanoparticles Primary CLL Cell Transfection. Pharmaceutics, 2020, 12, 520.	4.5	16
143	Cytogenetic risk score maintains its prognostic significance in <scp>AML</scp> patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation. American Journal of Hematology, 2020, 95, 1135-1141.	4.1	6
144	Conditioning Regimen-Specific Patterns and Determinants of Acute Severe Organ Toxicity Following Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, S36-S37.	2.0	0

#	ARTICLE	IF	CITATIONS
145	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1784-1802.	2.0	14
146	CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges. <i>Current Research in Translational Medicine</i> , 2020, 68, 111-118.	1.8	30
147	Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. <i>Journal of Hematology and Oncology</i> , 2020, 13, 87.	17.0	44
148	Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. <i>Lancet Haematology</i> , 2020, 7, e284-e294.	4.6	78
149	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. <i>Lancet Haematology</i> , 2020, 7, e157-e167.	4.6	319
150	LDH and renal function are prognostic factors for long-term outcomes of multiple myeloma patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1736-1743.	2.4	11
151	Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 296-304.	0.4	5
152	Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells. <i>Leukemia</i> , 2020, 34, 1939-1942.	7.2	12
153	Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. <i>Bone Marrow Transplantation</i> , 2020, 55, 1093-1102.	2.4	78
154	Decision-analytic modeling as a tool for selecting optimal therapy incorporating hematopoietic stem cell transplantation in patients with hematological malignancy. <i>Bone Marrow Transplantation</i> , 2020, 55, 1220-1228.	2.4	1
155	Salivary Microbial and Metabolic Determinants of Oral Mucositis in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S50.	2.0	1
156	CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. <i>Bone Marrow Transplantation</i> , 2020, 55, 1525-1532.	2.4	17
157	Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response. <i>Molecular Carcinogenesis</i> , 2020, 59, 736-744.	2.7	24
158	Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib. <i>EJHaem</i> , 2020, 1, 94-102.	1.0	8
159	Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients. , 2020, 8, e000148.		42
160	Comparing Car T Cells Toxicities Grading Systems: Application of Astct Grading System and Implications for Management. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S40-S41.	2.0	0
161	<sc>CD34</sc>+ cell dose effects on clinical outcomes after Tâ€cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (<sc>FBMT</sc>). <i>American Journal of Hematology</i> , 2020, 95, 892-899.	4.1	18
162	Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. <i>Blood Advances</i> , 2020, 4, 676-686.	5.2	101

#	ARTICLE	IF	CITATIONS
163	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020, 105, 47-58.	3.5	51
164	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with <i>FLT3</i> -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1507-1516.	3.5	91
165	Mechanism of HPSE Gene SNPs Function: From Normal Processes to Inflammation, Cancerogenesis and Tumor Progression. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1221, 231-249.	1.6	6
166	Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 2766-2775.	7.2	30
167	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. <i>Bone Marrow Transplantation</i> , 2020, 55, 1114-1125.	2.4	97
168	CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma: a Safety and Efficacy Study. <i>Blood</i> , 2020, 136, 34-34.	1.4	11
169	Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia. <i>Oncotarget</i> , 2020, 11, 2233-2245.	1.8	4
170	Summary of Scientific and Statistical Methods, Study Endpoints and Definitions for Observational and Registry-Based Studies in Hematopoietic Cell Transplantation. <i>Clinical Hematology International</i> , 2020, 2, 2.	1.7	66
171	Practicing Clinical Hematology During the COVID-19 Outbreak: A Challenge Like No Other. <i>Clinical Hematology International</i> , 2020, 2, 41.	1.7	1
172	COVID-19 in Hematologic Malignancies: Big Challenges. <i>Clinical Hematology International</i> , 2020, 2, 173.	1.7	4
173	Weathering the storm: COVID-19 infection in patients with hematological malignancies. <i>Journal of Zhejiang University: Science B</i> , 2020, 21, 921-939.	2.8	2
174	Looking Ahead: Clinical Hematology International Turns One. <i>Clinical Hematology International</i> , 2020, 2, 1.	1.7	1
175	Reduced Intensity Vs. Non-Myeloablative Conditioning Regimens for Haploidentical Transplantation in Complete Remission Acute Myeloid Leukemia: A Study from the ALWP of the EBMT. <i>Blood</i> , 2020, 136, 9-9.	1.4	0
176	A Novel Inflammatory Index Is Sufficient to Identify Hemophagocytic Lymphohistiocytosis in Adult Patients with Hematologic Malignancies. <i>Blood</i> , 2020, 136, 1-2.	1.4	0
177	Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Transplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2020, 136, 26-27.	1.4	0
178	Comparison of Reduced Intensity Conditioning - Allogeneic HCT and Autologous HCT for Elderly Patients with Acute Lymphoblastic Leukemia. an Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2020, 136, 6-7.	1.4	0
179	Evaluating Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated on the GMALL Protocol. <i>Blood</i> , 2020, 136, 28-29.	1.4	0
180	Outcomes of Allogeneic Hematopoietic Cell Transplantation with Cord Blood Versus Mismatched Unrelated Donor with Post-Transplant Cyclophosphamide in Acute Myeloid Leukemia: An Analysis from the ALWP of the EBMT. <i>Blood</i> , 2020, 136, 5-6.	1.4	0

#	ARTICLE	IF	CITATIONS
181	A Phase II Study of Bisantrene in Patients with Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 5-6.	1.4	0
182	Hematopoietic stem cell transplantation for adult patients with isolated <i>NPM1</i> mutated acute myeloid leukemia in first remission. <i>American Journal of Hematology</i> , 2019, 94, 231-239.	4.1	15
183	Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide. <i>Leukemia</i> , 2019, 33, 230-239.	7.2	36
184	European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation. <i>Leukemia</i> , 2019, 33, 508-517.	7.2	45
185	Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis. <i>Bone Marrow Transplantation</i> , 2019, 54, 531-539.	2.4	19
186	Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 519-530.	2.4	54
187	Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. <i>Bone Marrow Transplantation</i> , 2019, 54, 44-52.	2.4	59
188	Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia. <i>EClinicalMedicine</i> , 2019, 15, 33-41.	7.1	8
189	Haploidentical stem cell transplantation (HaploSCT) for patients with acute leukemia—an update on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 713-718.	2.4	13
190	The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators. <i>Biochemical Pharmacology</i> , 2019, 168, 412-428.	4.4	12
191	A simplified method for detection of <i>N</i> -terminal valine adducts in patients receiving treosulfan. <i>Rapid Communications in Mass Spectrometry</i> , 2019, 33, 1635-1642.	1.5	7
192	Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2251-2260.	2.0	16
193	Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2008-2016.	2.0	20
194	Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2019, 12, 68.	17.0	22
195	Risk factors and implications of oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2019, 103, 402-409.	2.2	27
196	The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5362.	4.1	29
197	Safety, Resistance, and Efficacy Results from a Phase IIIb Study of Conventional- and Double-Dose Oseltamivir Regimens for Treatment of Influenza in Immunocompromised Patients. <i>Infectious Diseases and Therapy</i> , 2019, 8, 613-626.	4.0	19
198	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. <i>Leukemia</i> , 2019, 33, 2767-2778.	7.2	47

#	ARTICLE	IF	CITATIONS
199	Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. <i>Lancet Haematology</i> , 2019, 6, e573-e584.	4.6	140
200	Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2019, 12, 108.	17.0	51
201	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2113-2123.	2.0	77
202	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2305-2321.	2.0	132
203	A novel method for detecting the cellular stemness state in normal and leukemic human hematopoietic cells can predict disease outcome and drug sensitivity. <i>Leukemia</i> , 2019, 33, 2061-2077.	7.2	13
204	Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. <i>Haematologica</i> , 2019, 104, 929-936.	3.5	23
205	Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16). <i>Genes Chromosomes and Cancer</i> , 2019, 58, 516-520.	2.8	4
206	GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. <i>Lancet Haematology</i> , 2019, 6, e89-e99.	4.6	47
207	Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 3566-3573.	4.1	17
208	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1975-1983.	2.0	61
209	Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 2013-2019.	2.4	21
210	Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2019, 186, 767-776.	2.5	31
211	Performance of Prognostic Models in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Comparison. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S70-S71.	2.0	0
212	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) – an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 1868-1880.	2.4	86
213	A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2019, 60, 2404-2414.	1.3	15
214	Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1944-1952.	7.2	23
215	Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. <i>Leukemia</i> , 2019, 33, 2324-2330.	7.2	33
216	Fertility preservation from the point of view of hematopoietic cell transplant specialists – a worldwide-web-based survey analysis. <i>Bone Marrow Transplantation</i> , 2019, 54, 1747-1755.	2.4	5



#	ARTICLE	IF	CITATIONS
217	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplantation, 2019, 54, 1525-1552.	2.4	218
218	Shaping of CD56 <sup>bri</sup> Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis. Frontiers in Immunology, 2019, 10, 547.	4.8	16
219	Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica, 2019, 104, 1782-1788.	3.5	48
220	Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplantation, 2019, 54, 1643-1650.	2.4	254
221	Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI. Blood Advances, 2019, 3, 1950-1960.	5.2	9
222	External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation. Blood Advances, 2019, 3, 1881-1890.	5.2	73
223	Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. Blood Cancer Journal, 2019, 9, 88.	6.2	39
224	PAR1 Expression Predicts Clinical G-CSF CD34 <sup>+</sup> HSPC Mobilization and Repopulation Potential in Transplanted Patients. HemaSphere, 2019, 3, e288.	2.7	4
225	HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis. Biology of Blood and Marrow Transplantation, 2019, 25, 114-120.	2.0	27
226	ASBMT Statement on Routine Prophylaxis for Central Nervous System Recurrence of Acute Lymphoblastic Leukemia following Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, e86-e88.	2.0	8
227	Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia. Leukemia, 2019, 33, 686-695.	7.2	24
228	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, e76-e85.	2.0	85
229	Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT. European Journal of Cancer, 2019, 106, 212-219.	2.8	13
230	Deferasirox selectively induces cell death in the clinically relevant population of leukemic CD34 <sup>+</sup> CD38 <sup>+</sup> cells through iron chelation, induction of ROS, and inhibition of HIF1 $\alpha$ expression. Experimental Hematology, 2019, 70, 55-69.e4.	0.4	16
231	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia â€” a matched pair analysis by the Acute Leukaemia Working Party of EBMT. British Journal of Haematology, 2019, 184, 782-787.	2.5	82
232	Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. Lancet Haematology, 2019, 6, e67-e78.	4.6	146
233	Reply: Letter to the Editor Regarding â€œAutologous Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysisâ€. Biology of Blood and Marrow Transplantation, 2019, 25, e114-e115.	2.0	0
234	Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma. Acta Haematologica, 2019, 141, 84-90.	1.4	10



#	ARTICLE	IF	CITATIONS
235	Anti- $\alpha 4\beta 7$ integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease. Bone Marrow Transplantation, 2019, 54, 987-993.	2.4	41
236	Is fluorescence <i>in-situ</i> hybridization sufficient in patients with myelodysplastic syndromes and insufficient cytogenetic testing?. Leukemia and Lymphoma, 2019, 60, 764-771.	1.3	3
237	The effect of NIMA matching in adult unrelated mismatched hematopoietic stem cell transplantation â€“ a joint study of the Acute Leukemia Working Party of the EBMT and the CIBMTR. Bone Marrow Transplantation, 2019, 54, 849-857.	2.4	2
238	Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma. Blood, 2019, 134, 1531-1531.	1.4	3
239	Lactate Dehydrogenase Is a Key Prognostic Factor in Acute Myeloid Leukemia and Lymphoma Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2019, 134, 3304-3304.	1.4	3
240	Predictive Model of Early Relapse in Newly Diagnosed Multiple Myeloma: Analysis from a Pooled Dataset. Blood, 2019, 134, 2130-2130.	1.4	1
241	Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells. Blood, 2019, 134, 1947-1947.	1.4	2
242	Upregulation of Senescent/Exhausted Phenotype of CAR T Cells and Induction of Both Treg and Myeloid Suppressive Cells Correlate with Reduced Response to CAR T Cell Therapy in Relapsed/Refractory B Cell Malignancies. Blood, 2019, 134, 3234-3234.	1.4	12
243	Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies. Blood, 2019, 134, 4009-4009.	1.4	8
244	Current Status and Perspectives of Irradiation-Based Conditioning Regimens for Patients with Acute Leukemia Undergoing Hematopoietic Stem Cell Transplantation. Clinical Hematology International, 2019, 1, 19.	1.7	15
245	Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: In vivo T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study. Clinical Hematology International, 2019, 1, 58.	1.7	46
246	Fecal Microbiota Transplantation for Treatment of Acute Graft-versus-Host Disease. Clinical Hematology International, 2019, 1, 28.	1.7	20
247	Clinical Hematology International: Why a New Journal in Hematology?. Clinical Hematology International, 2019, 1, 1.	1.7	0
248	Long-term follow-up of patients (pts) with relapsed or refractory (r/r) follicular lymphoma (FL) treated with copanlisib.. Journal of Clinical Oncology, 2019, 37, 7553-7553.	1.6	0
249	Immunophenotyping and Function of Peripheral Blood Mononuclear Cells in Patients Undergoing Unrelated Allogeneic Transplantation with Post-Transplantation Cyclophosphamide in Combination with ATG Anti-Graft Versus Host Disease Prophylaxis. Blood, 2019, 134, 1989-1989.	1.4	0
250	Maintenance 5-Azactidine May Improve Outcomes after Allogeneic Stem-Cell Transplantation in High-Risk AML and MDS Patients. Blood, 2019, 134, 3302-3302.	1.4	1
251	Oral Mucositis Is Associated with Distinctive Patterns of Oral Microbiota Injury in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2019, 134, 3265-3265.	1.4	2
252	Maintaining the Cellular Anti-Viral and Anti-Leukemic Activities in GvHD Patients Undergoing Extracorporeal Photophoresis Therapy. Blood, 2019, 134, 3287-3287.	1.4	0

#	ARTICLE	IF	CITATIONS
253	Early Organ Toxicity Following Allogeneic Hematopoietic Stem Cell Transplantation Differs By Conditioning Regimen. <i>Blood</i> , 2019, 134, 4489-4489.	1.4	2
254	Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management. <i>Blood</i> , 2019, 134, 4458-4458.	1.4	0
255	Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1001-1009.	2.4	23
256	Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1657-1663.	2.0	11
257	Tâ€cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3â€ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2018, 93, 736-744.	4.1	21
258	Primary plasma cell leukemia in the era of novel agents for myeloma â€“ a multicenter retrospective analysis of outcome. <i>Leukemia Research</i> , 2018, 68, 9-14.	0.8	14
259	AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 683-691.	2.4	13
260	Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1357-1366.	2.5	8
261	Attenuated DNA damage responses and increased apoptosis characterize human hematopoietic stem cells exposed to irradiation. <i>Scientific Reports</i> , 2018, 8, 6071.	3.3	25
262	Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT. <i>European Journal of Cancer</i> , 2018, 96, 73-81.	2.8	40
263	Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT. <i>American Journal of Hematology</i> , 2018, 93, 859-866.	4.1	28
264	Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 937-944.	2.0	37
265	Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2018, 53, 617-624.	2.4	45
266	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	30.7	216
267	Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 535-555.	2.4	75
268	Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 751-757.	2.0	39
269	Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 422-430.	2.4	24
270	The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 521-534.	2.4	168

#	ARTICLE	IF	CITATIONS
271	Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Haematology</i> , 2018, 5, e34-e43.	4.6	77
272	Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1548-1552.	2.4	6
273	Peripheral T cell lymphoma, not otherwise specified (PTCLâ€NOS). A new prognostic model developed by the International T cell Project Network. <i>British Journal of Haematology</i> , 2018, 181, 760-769.	2.5	49
274	Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy. <i>Haematologica</i> , 2018, 103, e469-e472.	3.5	90
275	ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1119-1124.	2.0	33
276	The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. <i>Haematologica</i> , 2018, 103, 1191-1197.	3.5	90
277	Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study. <i>American Journal of Hematology</i> , 2018, 93, 769-777.	4.1	22
278	Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. <i>Bone Marrow Transplantation</i> , 2018, 53, 1139-1148.	2.4	117
279	Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1102-1114.	6.3	41
280	Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitorâ€™Enriched Cord Blood, to Double Cord Blood Unit Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1463-1470.	2.0	31
281	Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 228-241.	2.0	43
282	Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 507-513.	2.0	10
283	Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. <i>American Journal of Hematology</i> , 2018, 93, 246-253.	4.1	52
284	Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. <i>Nature Medicine</i> , 2018, 24, 1867-1876.	30.7	179
285	Single-Dose Daily Fractionation Is Not Inferior to Twice-a-Day Fractionated Total-Body Irradiation Before Allogeneic Stem Cell Transplantation for Acute Leukemia: A Useful Practice Simplification Resulting From the SARASIN Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 515-526.	0.8	25
286	Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 9-16.	4.4	13
287	Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects. <i>Frontiers in Immunology</i> , 2018, 9, 2207.	4.8	21
288	Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. <i>Journal of Hematology and Oncology</i> , 2018, 11, 127.	17.0	17

#	ARTICLE	IF	CITATIONS
289	Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT. American Journal of Hematology, 2018, 93, 1532-1542.	4.1	10
290	Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia. American Journal of Hematology, 2018, 93, 1485-1492.	4.1	93
291	Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. Journal of Hematology and Oncology, 2018, 11, 110.	17.0	41
292	Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?. Blood Advances, 2018, 2, 1180-1186.	5.2	35
293	Prevention and treatment of relapse after stem cell transplantation with immunotherapy. Bone Marrow Transplantation, 2018, 53, 664-672.	2.4	11
294	Role of oral examination in newly diagnosed multiple myeloma patients: A safe and simple way to detect light chain amyloidosis. Oral Diseases, 2018, 24, 1343-1348.	3.0	5
295	CAR T cells induce a complete response in refractory Burkitt Lymphoma. Bone Marrow Transplantation, 2018, 53, 1583-1585.	2.4	25
296	The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation. Leukemia, 2018, 32, 1787-1794.	7.2	36
297	Identification of strong intron enhancer in the heparanase gene: effect of functional rs4693608 variant on HPSE enhancer activity in hematological and solid malignancies. Oncogenesis, 2018, 7, 51.	4.9	16
298	Reduced Relapse Incidence with FLAMSA+RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 2224-2232.	2.0	12
299	Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. American Journal of Hematology, 2018, 93, 1211-1219.	4.1	20
300	Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. American Journal of Hematology, 2018, 93, 1142-1152.	4.1	91
301	Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study. Biology of Blood and Marrow Transplantation, 2018, 24, 2265-2270.	2.0	10
302	Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 2365-2370.	2.0	61
303	Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. Biology of Blood and Marrow Transplantation, 2018, 24, 1406-1414.	2.0	44
304	Baseline Renal Function and Albumin are Powerful Predictors for Allogeneic Transplantation-Related Mortality. Biology of Blood and Marrow Transplantation, 2018, 24, 1685-1691.	2.0	22
305	Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). British Journal of Haematology, 2018, 183, 411-420.	2.5	27
306	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 533-540.	0.4	9

#	ARTICLE	IF	CITATIONS
307	Repeated Courses of Orally Administered Fecal Microbiota Transplantation for the Treatment of Steroid Resistant and Steroid Dependent Intestinal Acute Graft Vs. Host Disease: A Pilot Study (NCT) Tj ETQq1 1 0.784314 rgBT /Overlo	1.4	11
308	Incidence of Acute Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation over Time: A Study from the Transplant Complications and Chronic Malignancies Working Party of the EBMT. Blood, 2018, 132, 2120-2120.	1.4	11
309	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. Blood, 2018, 132, 3032-3032.	1.4	6
310	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). Blood, 2018, 132, 577-577.	1.4	39
311	Incidence of HLA Loss in a Global Multicentric Cohort of Post-Transplantation Relapses: Results from the Hlaloss Collaborative Study. Blood, 2018, 132, 818-818.	1.4	19
312	Inferior Outcome of Allogeneic Stem Cell Transplantation in First Complete Remission for Secondary AML As Compared to De Novo Disease: Results from a Retrospective, Registry-Based Analysis on Behalf of the Acute Leukemia Working Party of the EBMT. Blood, 2018, 132, 2166-2166.	1.4	7
313	Post-Transplant Sorafenib Improves Overall Survival in FLT3 Mutated AML: A Report from the EBMT Acute Leukemia Working Party. Blood, 2018, 132, 708-708.	1.4	4
314	Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma. Blood, 2018, 132, 1595-1595.	1.4	10
315	Outcomes for Patients with High-Risk Relapsed or Refractory Indolent B-Cell Lymphoma Treated with Copanlisib in the CHRONOS-1 Study. Blood, 2018, 132, 395-395.	1.4	4
316	Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma. Blood, 2018, 132, 1613-1613.	1.4	1
317	Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses of diabetic patients from the phase II CHRONOS-1 study.. Journal of Clinical Oncology, 2018, 36, 7570-7570.	1.6	1
318	Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission. Oncotarget, 2018, 9, 3379-3393.	1.8	40
319	STK405759 as a combination therapy with bortezomib or dexamethasone, in in vitro and in vivo multiple myeloma models. Oncotarget, 2018, 9, 31367-31379.	1.8	4
320	Single cell analysis of multiple myeloma.. Journal of Clinical Oncology, 2018, 36, 8026-8026.	1.6	1
321	Comorbidity-Associated Risk of Overall Mortality Following Hematopoietic Stem-Cell Transplantation Is Regimen-Dependent: A Study from the Acute Leukemia Working Party of the EBMT. Blood, 2018, 132, 203-203.	1.4	0
322	No Inhibition of Anti-Viral and Anti-Leukemia Effects By Extracorporeal Photopheresis Therapy. Blood, 2018, 132, 3399-3399.	1.4	1
323	Outcome of Soft-Tissue Plasmocytomas in Newly Diagnosed Multiple Myeloma Patients Treated with New Drugs. Blood, 2018, 132, 3235-3235.	1.4	0
324	The Role of Anti-Thymocyte Globulin (ATG) in Patients with AML Transplanted in CR1 from Sibling and Unrelated Donors with or without Measurable Residual Disease (MRD) at the Time of Allogeneic Stem Cell Transplantation: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Blood, 2018, 132, 248-248.	1.4	1



#	ARTICLE	IF	CITATIONS
325	FLT3 and NPM1 Are Powerful Determinants of Outcome in Acute Myeloid Leukemia Patients Treated with Autologous Stem Cell Transplantation: An Analysis By the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2018, 132, 609-609.	1.4	0
326	Inhibition of WIP1 Phosphatase in Multiple Myeloma Overcomes Bortezomib Resistance and Promotes Cell Death Via ER Stress-Induced Apoptotic JNK/c-Jun Signaling and Downregulation of Inhibitors of Apoptosis Proteins (IAPs). <i>Blood</i> , 2018, 132, 1366-1366.	1.4	0
327	Ibrutinib, Bendamustine, Rituximab Combination for Relapsed and Refractory Aggressive B Cell Lymphoma – Interim Analysis of Phase II Clinical Trial. <i>Blood</i> , 2018, 132, 4186-4186.	1.4	3
328	Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation – a retrospective national multicenter study. <i>Annals of Hematology</i> , 2017, 96, 575-579.	1.8	5
329	The gastrointestinal tract: properties and role in allogeneic hematopoietic stem cell transplantation. <i>Expert Review of Hematology</i> , 2017, 10, 315-326.	2.2	7
330	Gender disparities in the functional significance of anemia among apparently healthy adults. <i>European Journal of Haematology</i> , 2017, 98, 435-442.	2.2	5
331	High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. <i>Haematologica</i> , 2017, 102, 160-167.	3.5	49
332	Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT. <i>Cancer</i> , 2017, 123, 1965-1970.	4.1	31
333	Validation of the acute leukemia – EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort. <i>American Journal of Hematology</i> , 2017, 92, 429-434.	4.1	33
334	Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2017, 102, 1066-1074.	3.5	40
335	Isolated Extramedullary Relapse of Acute Leukemia after Allogeneic Stem Cell Transplantation: Different Kinetics and Better Prognosis than Systemic Relapse. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1087-1094.	2.0	47
336	Peroxisome proliferator-activated receptor gamma (PPAR $\gamma$ ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target. <i>EMBO Molecular Medicine</i> , 2017, 9, 508-530.	6.9	11
337	ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT. <i>American Journal of Hematology</i> , 2017, 92, 789-796.	4.1	17
338	Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission – Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Cancer</i> , 2017, 123, 824-831.	4.1	32
339	Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning. <i>American Journal of Hematology</i> , 2017, 92, 1011-1019.	4.1	14
340	Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT. <i>American Journal of Hematology</i> , 2017, 92, 653-659.	4.1	18
341	Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 65, 1-7.	1.4	30
342	Anti-thymocyte globulin as graft- versus -host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2017, 102, 224-234.	3.5	108



#	ARTICLE	IF	CITATIONS
343	The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors. American Journal of Hematology, 2017, 92, 259-268.	4.1	12
344	Impact of <scp>FAB</scp> classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in <scp>CR</scp> 1: An analysis of 1690 patients from the acute leukemia working party of <scp>EBMT</scp>. American Journal of Hematology, 2017, 92, 344-350.	4.1	18
345	Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica, 2017, 102, 1913-1922.	3.5	52
346	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood, 2017, 130, 2610-2618.	1.4	90
347	Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT. Haematologica, 2017, 102, 2134-2140.	3.5	33
348	Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers. Clinical Cancer Research, 2017, 23, 6790-6801.	7.0	43
349	Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission. American Journal of Hematology, 2017, 92, 1318-1323.	4.1	21
350	Machine learning for prediction of 30-day mortality after ST elevation myocardial infraction: An Acute Coronary Syndrome Israeli Survey data mining study. International Journal of Cardiology, 2017, 246, 7-13.	1.7	77
351	An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia. Clinical Cancer Research, 2017, 23, 6478-6486.	7.0	28
352	Prognostic Scoring Systems in Allogeneic Hematopoietic Stem Cell Transplantation: Where Do We Stand?. Biology of Blood and Marrow Transplantation, 2017, 23, 1839-1846.	2.0	36
353	Long-Term Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Bone Marrow Failure Syndromes: A Report From Eurocord, Cord Blood Committee and Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1939-1948.	2.0	19
354	Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 278-284.	2.0	38
355	Ponatinib reduces viability, migration, and functionality of human endothelial cells. Leukemia and Lymphoma, 2017, 58, 1455-1467.	1.3	46
356	The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway. Clinical Cancer Research, 2017, 23, 1733-1747.	7.0	28
357	Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012. Clinical Genitourinary Cancer, 2017, 15, 163-167.	1.9	3
358	Identification of miRSNPs associated with the risk of multiple myeloma. International Journal of Cancer, 2017, 140, 526-534.	5.1	8
359	Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. Biology of Blood and Marrow Transplantation, 2017, 23, 44-52.	2.0	49
360	Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of <scp>EBMT</scp>. British Journal of Haematology, 2017, 176, 431-439.	2.5	26

#	ARTICLE	IF	CITATIONS
361	Long-Term Safety of Transplanting Human Bone Marrow Stromal Cells into the Extravascular Spaces of the Choroid of Rabbits. <i>Stem Cells International</i> , 2017, 2017, 1-13.	2.5	7
362	Ethnic variation in medical and lifestyle risk factors for B cell non-Hodgkin lymphoma: A case-control study among Israelis and Palestinians. <i>PLoS ONE</i> , 2017, 12, e0171709.	2.5	14
363	From patient centered risk factors to comprehensive prognostic models: a suggested framework for outcome prediction in umbilical cord blood transplantation. <i>Stem Cell Investigation</i> , 2017, 4, 39-39.	3.0	4
364	Copanlisib in patients with relapsed or refractory follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7535-7535.	1.6	5
365	Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Oncotarget</i> , 2017, 8, 418-429.	1.8	8
366	Dissecting the mechanisms involved in anti-human T-lymphocyte immunoglobulin (ATG)-induced tolerance in the setting of allogeneic stem cell transplantation - potential implications for graft versus host disease. <i>Oncotarget</i> , 2017, 8, 90748-90765.	1.8	6
367	Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT. <i>Oncotarget</i> , 2017, 8, 112972-112979.	1.8	22
368	The CXCR4 Antagonist BL-8040 Induces a Robust Mobilization of CD34+CD38 <sup>hi</sup> CD45RA <sup>hi</sup> CD90 <sup>+</sup> CD49f <sup>+</sup> HSCs with Long-Term and Secondary Myeloid and Lymphoid Repopulating Activity. <i>Blood</i> , 2017, 130, 660-660.	1.4	1
369	Transplantation Outcome By Disease Risk and Donor Type over Time: An Analysis of 100,000 Allogeneic Stem Cell Transplantation on Behalf of the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2017, 130, 668-668.	1.4	0
370	Donor Age Determines Outcome in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Cell Transplantation. <i>Blood</i> , 2017, 130, 850-850.	1.4	0
371	Outcomes of Graft Failures after Umbilical Cord Blood Transplantation in Acute Leukemia: A Study from Eurocord and the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2017, 130, 661-661.	1.4	0
372	Haploidentical T-Repleted Stem Cell Transplantation (SCT) Has Comparable Survival to 10/10 and 9/10 Unrelated SCT in Poor-Cytogenetics Risk Acute Myeloid Leukemia in First Complete Remission: A Study on Behalf of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2017, 130, 852-852.	1.4	0
373	Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. <i>Haematologica</i> , 2016, 101, 256-262.	3.5	42
374	Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. <i>Cancer</i> , 2016, 122, 2050-2056.	4.1	40
375	Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 710-718.	2.8	28
376	Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome <sup>+</sup> positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2016, 122, 2941-2951.	4.1	140
377	Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2016, 122, 1880-1887.	4.1	31
378	Best allogeneic transplantation approach for <sc>AML</sc> patients in first <sc>CR</sc>: is delayed unrelated donor bone marrow transplantation better than immediate unrelated cord blood transplantation?. <i>European Journal of Haematology</i> , 2016, 97, 215-216.	2.2	0

#	ARTICLE	IF	CITATIONS
379	Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status. <i>Haematologica</i> , 2016, 101, e34-e37.	3.5	12
380	Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2016, 101, 773-780.	3.5	35
381	Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT. <i>Oncologist</i> , 2016, 21, 377-383.	3.7	10
382	Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies. <i>Annals of Medicine</i> , 2016, 48, 428-439.	3.8	32
383	Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT. <i>Haematologica</i> , 2016, 101, 248-255.	3.5	19
384	Peripheral blood stem cell versus bone marrow transplantation: A perspective from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Experimental Hematology</i> , 2016, 44, 567-573.	0.4	21
385	Associations between B-cell non-Hodgkin lymphoma and exposure, persistence and immune response to hepatitis B. <i>Haematologica</i> , 2016, 101, e303-e305.	3.5	14
386	Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2016, 9, 79.	17.0	42
387	Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>European Journal of Haematology</i> , 2016, 96, 90-97.	2.2	16
388	Established and emerging targeted therapies in the myelodysplastic syndromes. <i>Expert Review of Hematology</i> , 2016, 9, 997-1005.	2.2	2
389	Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. <i>Haematologica</i> , 2016, 101, 879-883.	3.5	126
390	Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the EBMT database. <i>Haematologica</i> , 2016, 101, e352-e354.	3.5	49
391	Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. <i>Journal of Hematology and Oncology</i> , 2016, 9, 118.	17.0	50
392	Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD. <i>Blood</i> , 2016, 128, 1979-1986.	1.4	66
393	Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 277-283.	2.0	12
394	Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications. <i>Expert Review of Hematology</i> , 2016, 9, 297-314.	2.2	34
395	Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 23-26.	2.0	70
396	Reprint of: Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S15-S18.	2.0	47

#	ARTICLE	IF	CITATIONS
397	VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 329-334.e1.	0.4	26
398	Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E16-22.	7.1	73
399	Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2016, 374, 43-53.	27.0	436
400	Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study. <i>Leukemia and Lymphoma</i> , 2016, 57, 63-69.	1.3	25
401	The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 2745-2745.	1.4	3
402	Comparison of Allogeneic Stem Cell Transplantation for Transformed Acute Myeloid Leukemia Derived from MDS, CMML or MPN. a Report of the Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2016, 128, 3499-3499.	1.4	2
403	Impact of Immune Reconstitution (IR) and Graft-Versus-Host Disease (GvHD) on Clinical Outcomes after Treatment with Donor T Cells Transduced to Express the Herpes Simplex Virus Thymidine-Kinase Suicide Gene (TK cells) in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation (HSCT). <i>Blood</i> , 2016, 128, 4599-4599.	1.4	3
404	Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , 2016, 128, 479-479.	1.4	32
405	Primary Plasma Cell Leukemia Has a Poor Prognosis Even in the Era of Novel Agents - a Multicenter Case Series. <i>Blood</i> , 2016, 128, 5699-5699.	1.4	1
406	An EBMT Prospective Non-Interventional Study of Outcomes and Toxicity of Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second Generation Tyrosine Kinase Inhibitors. <i>Blood</i> , 2016, 128, 628-628.	1.4	1
407	Allogeneic Genetically Modified T Cells (HSV-TK) As Adjunctive Treatment in Haploidentical Hematopoietic Stem-Cell Transplantation (haplo-HSCT) of Adult Patients with High-Risk Hematological Malignancies: A Pair-Matched Analysis from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2016, 128, 672-672.	1.4	6
408	Autologous Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT. <i>Blood</i> , 2016, 128, 678-678.	1.4	7
409	The Disease Risk Index Is a Robust Tool for Allogeneic Hematopoietic Stem Cell Transplantation Risk Stratification: An Independent Validation Study on a Large Cohort of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 988-988.	1.4	1
410	Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8018-8018.	1.6	8
411	Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study. <i>PLoS ONE</i> , 2016, 11, e0150637.	2.5	28
412	The novel compound STK405759 is a microtubule-targeting agent with potent and selective cytotoxicity against multiple myeloma in vitro and in vivo. <i>Oncotarget</i> , 2016, 7, 62572-62584.	1.8	3
413	High CD34+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia "an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Oncotarget</i> , 2016, 7, 27255-27266.	1.8	53
414	The High Affinity CXCR4 Inhibitor, BL-8040, Induces Apoptosis of AML Blasts and Their Terminal Differentiation By Blocking AKT/ERK Survival Signals and Downregulating BCL-2, MCL-1 and Cyclin-D1 through Regulation of Mir-15a/16-1 Expression. <i>Blood</i> , 2016, 128, 767-767.	1.4	0



#	ARTICLE	IF	CITATIONS
415	Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT. <i>Blood</i> , 2016, 128, 3467-3467.	1.4	0
416	Objective Measures of Pre-Transplant Physiologic Fitness Are Strong Predictors of Very-Short Term Transplantation Related Mortality. <i>Blood</i> , 2016, 128, 2205-2205.	1.4	0
417	Prediction of Allogeneic Stem Cell Transplantation Mortality in Patients with Acute Leukemia (AL) Using the AL- European Society for Blood and Marrow Transplantation (EBMT) Risk Score in the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO) Data Set: A Study on Behalf of the AL Working Party (ALWP) of the EBMT and GITMO. <i>Blood</i> , 2016, 128, 989-989.	1.4	0
418	Impact of FAB Classification on Predicting Outcome in Acute Myeloid Leukemia, Not Otherwise Specified, Patients Undergoing Allogeneic Stem Cell Transplantation in CR1: An Analysis of 1690 Patients from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2016, 128, 2899-2899.	1.4	5
419	A Comparison of Fractionated Myeloablative Total Body Irradiation Schedules Combined with Chemotherapy As Conditioning for Allograft Bone Marrow Transplantation in Patients with Acute Leukemia: The Sarasin Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 981-981.	1.4	0
420	Development of a Risk Score for Prediction of Overall Survival Following Umbilical Cord Blood Transplantation in Acute Leukemia Patients: A Study from the Acute Leukemia Working Party (WP) and Paediatric Disease WP of the European Society for Blood and Marrow Transplantation (EBMT), and Eurocord. <i>Blood</i> , 2016, 128, 1169-1169.	1.4	2
421	An Alternative Donor Is a Valid Option Compared to a Matched-Unrelated in Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in CR2: A Report of 841 Patients from the EBMT Acute Leukemia Working Party. <i>Blood</i> , 2016, 128, 3497-3497.	1.4	0
422	Use of First or Second Generation TKI for CML after Allogeneic Stem Cell Transplantation: a Study By the CMWP of the EBMT. <i>Blood</i> , 2016, 128, 4685-4685.	1.4	2
423	The Use of Anti-Thymocyte Globulin Is Associated with Increased Chance of Survival Free from Relapse and Graft-Versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation for Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2016, 128, 666-666.	1.4	0
424	The Neglected Role of Hematologic Disorders in Pulmonary Embolism. <i>Journal of Cardiovascular Emergencies</i> , 2016, 2, 192-193.	0.2	0
425	T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis. <i>Haematologica</i> , 2015, 100, 558-564.	3.5	29
426	Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. <i>Blood</i> , 2015, 126, 2062-2069.	1.4	93
427	The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2015, 100, 683-689.	3.5	36
428	Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. <i>EBioMedicine</i> , 2015, 2, 2101-2109.	6.1	36
429	Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 years old: A study from the acute leukemia working party (<sc>ALWP</sc>) of the <sc>European group of blood and marrow transplantation (<sc>EBMT</sc>). <i>American Journal of Hematology</i> , 2015, 90, 719-724.	4.1	18
430	Bioactive magnetic near Infra-Red fluorescent core-shell iron oxide/human serum albumin nanoparticles for controlled release of growth factors for augmentation of human mesenchymal stem cell growth and differentiation. <i>Journal of Nanobiotechnology</i> , 2015, 13, 34.	9.1	43
431	Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. <i>Lancet Haematology</i> , 2015, 2, e384-e392.	4.6	46
432	Halofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 65.	8.6	15

#	ARTICLE	IF	CITATIONS
433	Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Leukemia Research</i> , 2015, 39, 933-937.	0.8	23
434	Effect of Cord Blood Processing on Transplantation Outcomes after Single Myeloablative Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 688-695.	2.0	16
435	Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3144-3151.	1.6	119
436	Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2015, 100, 859-869.	3.5	80
437	Predictive Limitations of Hematopoietic Stem Cell Transplantation Associated Mortality: A Machine Learning in-Silico Analysis of the EBMT - Acute Leukemia Working Party Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S310-S311.	2.0	2
438	Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1525-1536.	10.7	143
439	Epiretinal transplantation of human bone marrow mesenchymal stem cells rescues retinal and vision function in a rat model of retinal degeneration. <i>Stem Cell Research</i> , 2015, 15, 387-394.	0.7	45
440	Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Transplantation Chronic Myeloid Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1852-1855.	2.0	3
441	Higher Infection Rate After 7- Compared With 5-Day Cycle of Azacitidine in Patients With Higher-Risk Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e95-e99.	0.4	18
442	Chemotherapy Dose Adjustment for Obese Patients Undergoing Hematopoietic Stem Cell Transplantation: A Survey on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Oncologist</i> , 2015, 20, 50-55.	3.7	9
443	Phase 3, Placebo-Controlled, ASPIRE Study (TRC114968) of Eltrombopag (EPAG) Treatment of Thrombocytopenia (TCP) in Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Assessment of Clinical Benefit, Safety, and Tolerability. <i>Blood</i> , 2015, 126, 1661-1661.	1.4	1
444	Roneparstat (SST0001), an Innovative Heparanase (HPSE) Inhibitor for Multiple Myeloma (MM) Therapy: First in Man Study. <i>Blood</i> , 2015, 126, 3246-3246.	1.4	10
445	HLA Disparities Impact on Outcomes after Unmanipulated Haploidentical Hematopoietic Stem Cells Transplantation (HaploSCT) in Acute Leukemia: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2015, 126, 399-399.	1.4	2
446	Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and May Lead to Eradication of Measureable Disease. <i>Blood</i> , 2015, 126, 4218-4218.	1.4	10
447	An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study. <i>Blood</i> , 2015, 126, 827-827.	1.4	17
448	Impact of response to induction chemotherapy (CT) and prior paclitaxel (TXL)-based CT on the outcome of salvage high-dose chemotherapy (HDCT) for relapsed germ-cell tumors (GCT) in the modern era: An EBMT Solid Tumors Working Party study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4535-4535.	1.6	0
449	Conventional-dose (CDCT) versus high-dose chemotherapy (HDCT) in the salvage management of relapsed pure seminoma: Results from an international database.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15559-e15559.	1.6	0
450	Evaluation of the Impact of Non-Inherited Maternal Antigens on the Outcome of HLA Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation for Hematological Malignancies on Behalf of the ALWP of the EBMT and the CIBMTR. <i>Blood</i> , 2015, 126, 3226-3226.	1.4	0



#	ARTICLE	IF	CITATIONS
451	Allogeneic Stem Cell Transplantation for Elderly Patients with Intermediate-Risk Cytogenetic Acute Myeloid Leukemia and Internal Tandem Duplication of FLT3 (FLT3-ITD); A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). Blood, 2015, 126, 4364-4364.	1.4	0
452	Outcome of Patients with Myelofibrosis Relapsing after Allogeneic Stem Cell Transplant: A Retrospective Study By the Chronic Malignancies Working Party of EBMT. Blood, 2015, 126, 1958-1958.	1.4	0
453	A Machine Learning Based Model to Predict Two-Year Leukemia Free Survival in Cord Blood Transplantation for Acute Leukemia - a Data Mining Study, on Behalf of Eurocord, Cord Blood Committee and the Acute Leukemia Working Party of the EBMT. Blood, 2015, 126, 3211-3211.	1.4	3
454	Anti-Human T-Lymphocyte Immunoglobulin (ATG)-Induced T Regulatory Cells and Their Soluble Factors Suppress T Cell Proliferation: Potential Role in Allogeneic Stem Cell Transplantation. Blood, 2015, 126, 1889-1889.	1.4	0
455	Autologous Stem Cell Transplantation for Adult Acute Myelocytic Leukemia in First Remission: Better Outcome Following Busulfan and Melphalan Compared to Busulfan and Cyclophosphamide : A Retrospective Study from the Acute Leukemia Working Party of the EBMT. Blood, 2015, 126, 926-926.	1.4	0
456	Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with High-Risk AML in Complete Remission: A Survey from the ALWP of the EBMT. Blood, 2015, 126, 3105-3105.	1.4	0
457	Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia and 17p Abnormalities in First Complete Remission: A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). Blood, 2015, 126, 2021-2021.	1.4	0
458	Thiotepa-Based Conditioning for Allogeneic Stem Cell Transplantation (allo-HSCT) in Acute Lymphoblastic Leukaemia (ALL) - a Survey from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2015, 126, 4316-4316.	1.4	0
459	Comparison of Matched-Sibling Donors Versus Unrelated Donors in Allogeneic Stem Cell Transplantation (allo-SCT) for Primary Refractory Acute Myeloid Leukemia (PRF AML): A Report of 1041 Patients from the Acute Leukemia Working Party of the EBMT. Blood, 2015, 126, 196-196.	1.4	0
460	STK405759 As a Novel Tubulin Active Agent for Multiple Myeloma Therapy. Blood, 2015, 126, 5348-5348.	1.4	0
461	Allogeneic Stem Cell Transplantation for MDS Patients More Than 70 Years of Age: a Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party (CMWP) of the EBMT. Blood, 2015, 126, 4390-4390.	1.4	1
462	Biosimilar G-CSF Based Mobilization of Peripheral Blood Hematopoietic Stem Cells for Autologous and Allogeneic Stem Cell Transplantation. Theranostics, 2014, 4, 280-289.	10.0	42
463	Acquisition of an immunosuppressive protumorigenic macrophage phenotype depending on c-Jun phosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17582-17587.	7.1	45
464	Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica, 2014, 99, 1380-1386.	3.5	31
465	Single cell analysis exposes intratumor heterogeneity and suggests that FLT3-ITD is a late event in leukemogenesis. Experimental Hematology, 2014, 42, 457-463.	0.4	22
466	Transplantation of human bone marrow mesenchymal stem cells as a thin subretinal layer ameliorates retinal degeneration in a rat model of retinal dystrophy. Experimental Eye Research, 2014, 118, 135-144.	2.6	120
467	Nilotinib 300 mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response. Leukemia Research, 2014, 38, 310-315.	0.8	12
468	Single Infusion of Donor Mononuclear Early Apoptotic Cells as Prophylaxis for Graft-versus-Host Disease in Myeloablative HLA-Matched Allogeneic Bone Marrow Transplantation: A Phase I/IIa Clinical Trial. Biology of Blood and Marrow Transplantation, 2014, 20, 58-65.	2.0	50

#	ARTICLE	IF	CITATIONS
469	NK Cell Receptor NKp46 Regulates Graft-versus-Host Disease. Cell Reports, 2014, 7, 1809-1814.	6.4	33
470	Infusion of Donor Lymphocytes Genetically Engineered to Express the Herpes Simplex Virus Thymidine Kinase (HSV-TK) Suicide Gene after Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Preliminary Efficacy Data from the Randomized TK008 Study. Blood, 2014, 124, 2535-2535.	1.4	5
471	Prediction of Allogeneic HSCT Related Mortality in Acute Leukemia: Exploring Boundaries of Prediction through Machine Learning Based Modeling. a Data Mining Study from the Acute Leukemia Working Party (ALWP) of the EBMT. Blood, 2014, 124, 2568-2568.	1.4	2
472	Prevention of Chronic GvHD after HLA-Identical Sibling Peripheral Hematopoietic Stem Cell Transplantation with or without Anti-Lymphocyte Globulin (ATG). Results from a Prospective, Multicenter Randomized Phase III Trial (ATGfamilystudy). Blood, 2014, 124, 37-37.	1.4	9
473	Allogeneic HCT with Reduced Intensity Conditioning Versus Autologous HCT for >55 Years Old Patients with Acute Lymphoblastic Leukemia in First Complete Remission: An Analysis from Acute Leukemia Working Party of the EBMT. Blood, 2014, 124, 3974-3974.	1.4	2
474	RIC Allo-SCT with Flu/Bu in Comparison to Flu/Mel for AML Results in Similar Overall Survival: A Report from the ALWP of the EBMT. Blood, 2014, 124, 545-545.	1.4	2
475	Matching of MHC Class I Chain-Related Genes a and B Is Associated with Reduced Incidence of Severe Acute Graft-Versus-Host Disease after Unrelated Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 664-664.	1.4	3
476	Randomized Trial of Busulfan with Cyclophosphamide Versus Busulfan with Fludarabine As Preparative Regimen to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia: A Study from the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood, 2014, 124, 727-727.	1.4	1
477	Higher Doses of Antithymocyte Globulin (ATG) Increase the Risk of Relapse in Acute Myeloid Leukemia (AML) Patients Undergoing Matched Related Donor Allogeneic Transplantation in First Complete Remission (CR1): An Analysis from the Acute Leukemia Working Party of EBMT. Blood, 2014, 124, 729-729.	1.4	6
478	BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial. Blood, 2014, 124, 950-950.	1.4	11
479	Efficacy of HSV-TK <sup>+</sup> suicide gene donor lymphocytes after haploidentical transplantation (haplo-HSCT): Preliminary results of randomized TK008 study.. Journal of Clinical Oncology, 2014, 32, 7003-7003.	1.6	1
480	Continuous treatment (CT) versus fixed duration of therapy (FDT) in newly diagnosed myeloma patients: PFS1, PFS2, OS endpoints.. Journal of Clinical Oncology, 2014, 32, 8515-8515.	1.6	6
481	Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. Oncotarget, 2014, 5, 11283-11296.	1.8	130
482	Early Apoptotic Cells (ApoCell) As Prophylaxis of Graft-Versus-Host Disease in Myeloablative HLA-Matched Allogeneic Bone Marrow Transplantation Is Safe and Effective: 1 Year Follow-up. Blood, 2014, 124, 5866-5866.	1.4	0
483	Autologous Stem Cell Transplantation for Primary Mediastinal B Cell Lymphoma in the Rituximab Era: A Retrospective Study By the EBMT Lymphoma Working Party. Blood, 2014, 124, 1195-1195.	1.4	2
484	Influence of Preexisting Invasive Aspergillosis on Allo-HSCT Outcome: A Retrospective EBMT Analysis from the Infectious Diseases and Acute Leukemia Working Parties. Blood, 2014, 124, 185-185.	1.4	0
485	Safety and Efficacy of Thiotepa-Based Conditioning Therapy for Allogeneic Transplantation in Acute Myeloid Leukemia - a Survey from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood, 2014, 124, 3895-3895.	1.4	0
486	The Hierarchy of Alternative Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Poor Risk AML in CR1: 10/10 Matched Unrelated Donors Still to be Preferred over Haplo-Identical Donors or Umbilical Cord Blood. Blood, 2014, 124, 681-681.	1.4	0

#	ARTICLE	IF	CITATIONS
487	S1P Modulator FTY720 Targets Multiple Myeloma Cell Proliferation and Stromal Interactions Via CXCR4/CXCL12 and mTOR Pathways. <i>Blood</i> , 2014, 124, 4707-4707.	1.4	0
488	Haploidentical Versus Autologous Stem Cell Transplantation in Adult Acute Leukemia: A Matched Pair Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2014, 124, 2508-2508.	1.4	0
489	High Risk Advanced Stage Hodgkin Lymphoma Is Well Controlled with 2 Cycles of Escalated Beacopp Followed By 4 Cycles of ABVD in Patients Who Rapidly Achieve Metabolic CR on Interim PET/CT Scan. <i>Blood</i> , 2014, 124, 4442-4442.	1.4	0
490	The International Multiple Myeloma Research (IMMEnSE) Consortium: Genetics of Multiple Myeloma Risk and Prognosis. <i>Blood</i> , 2014, 124, 3421-3421.	1.4	0
491	Allogeneic Hematopoietic Cell Transplantation in AML with Normal Karyotype and NPM1 Mutated FLT3-ITD Negative: A Retrospective Analysis from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2014, 124, 1230-1230.	1.4	1
492	Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome; A More Favorable Outcome after Fludarabine and Treosulfan Conditioning. a Survey on Behalf of the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2014, 124, 1216-1216.	1.4	0
493	Unrelated Cord Blood Versus Non-T Cell Depleted Haploidentical Stem Cell Transplantation: Comparable Results in Adults with Acute Leukemia, a Eurocord and ALWP-EBMT Study. <i>Blood</i> , 2014, 124, 1227-1227.	1.4	0
494	Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140. <i>Clinical Cancer Research</i> , 2013, 19, 3495-3507.	7.0	56
495	Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan Plus Cyclophosphamide (Cy) Versus Total-Body Irradiation Plus Cy As Conditioning Regimen—A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 3549-3556.	1.6	143
496	Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. <i>Blood</i> , 2013, 121, 849-857.	1.4	209
497	Immunobiology and Pharmacologic Manipulation of Dendritic and Regulatory Cells. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-2.	3.3	3
498	Maintenance Therapy With Lenalidomide Significantly Improved Survival Of Young Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 2089-2089.	1.4	11
499	Thiotepa-Based Vs TBI-Based Myeloablative Conditioning Prior To Allogeneic Stem Cell Transplantation (HSCT) For Acute Myeloid Leukemia (AML) In First Complete Remission (CR1): A Retrospective Analysis From The ALWP Of The EBMT. <i>Blood</i> , 2013, 122, 2123-2123.	1.4	1
500	StemEx®(Copper Chelation Based) Ex Vivo Expanded Umbilical Cord Blood Stem Cell Transplantation (UCBT) Accelerates Engraftment and Improves 100 Day Survival In Myeloablated Patients Compared To a Registry Cohort Undergoing Double Unit UCBT: Results Of a Multicenter Study Of 101 Patients With Hematologic Malignancies. <i>Blood</i> , 2013, 122, 295-295.	1.4	21
501	Randomized Placebo-Controlled Phase III Study Of Perifosine Combined With Bortezomib and Dexamethasone In Relapsed, Refractory Multiple Myeloma Patients Previously Treated With Bortezomib. <i>Blood</i> , 2013, 122, 3189-3189.	1.4	6
502	The Use Of Tivoreg (Biosimilar Filgrastim XMO2) For Hematopoietic Stem Cell Mobilization In HLA Matched Sibling Donors For Allogeneic Stem Cell Transplantation To AML/MDS Patients. <i>Blood</i> , 2013, 122, 3275-3275.	1.4	2
503	The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells. <i>Blood</i> , 2013, 122, 3939-3939.	1.4	5
504	Treosulfan Based Conditioning Prior To Allogeneic Stem Cell Transplantation (HSCT) For Acute Myelogenous Leukemia (AML): A Retrospective Analysis From The ALWP Of The EBMT. <i>Blood</i> , 2013, 122, 545-545.	1.4	3

#	ARTICLE	IF	CITATIONS
505	Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients.. Journal of Clinical Oncology, 2013, 31, 8509-8509.	1.6	15
506	Efficacy of radioimmunotherapy-based conditioning with high-dose chemotherapy and autologous stem cell transplantation for transformed lymphoma.. Journal of Clinical Oncology, 2013, 31, 8556-8556.	1.6	0
507	Extreme Heterogeneity Of Myeloablative Total Body Irradiation (TBI) Techniques Across Europe: A Survey Of Acute Leukemia Working Party Of The EBMT. Blood, 2013, 122, 4565-4565.	1.4	0
508	Prediction Of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Related Mortality in Acute Leukemia: Generation Of a Machine Learning-Based Model Using The Data Set of The Acute Leukemia Working Party (ALWP) Of The EBMT. Blood, 2013, 122, 409-409.	1.4	5
509	Outcome Of Patients With HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma (ATL) Who Have Undergone Stem Cell Transplantation: A Retrospective Study Of The EBMT Lymphoma Working Party. Blood, 2013, 122, 3398-3398.	1.4	0
510	Missing HLA C Group 1 Ligand In Patients With AML and MDS Is Associated With Reduced Risk Of Relapse After Allogeneic Stem Cell Transplantation With Fludarabine and Treosulfan Reduced Toxicity Conditioning. Blood, 2013, 122, 4634-4634.	1.4	0
511	Donor Cell Derived Leukemia: Description Of 38 Cases and a Case Control Study. Blood, 2013, 122, 914-914.	1.4	0
512	Validation of Digital-PCR Analysis through Programmed imatinib Interruption in Q-RT-PCR Negative Chronic Myeloid Leukemia Patients. Blood, 2013, 122, 4040-4040.	1.4	0
513	Chemotherapy Dose Adjustment For Obese Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT): A Survey On Behalf Of The ALWP Of The EBMT. Blood, 2013, 122, 4535-4535.	1.4	0
514	Favorable Outcome For Patients With Lymphoid Malignancies Following Allogeneic Stem Cell Transplantation Using Fludarabine Treosulfan, Compared With Other Reduced Intensity Conditioning Regimen. Blood, 2013, 122, 3380-3380.	1.4	0
515	Jewish Immigrants Of Middle Eastern Origin Have a Lower Incidence Of Multiple Myeloma Compared To Both North African and European Jews In a Cohort Of 746,200 Israeli Men Followed From Late Adolescence. Blood, 2013, 122, 5346-5346.	1.4	0
516	Allogeneic Hematopoietic Stem-Cell Transplantation In AML and MDS Using Myeloablative Versus Reduced Intensity Conditioning: 10 Years Later. Blood, 2013, 122, 4635-4635.	1.4	0
517	Allogeneic Stem Cell Transplantation For Acute Myeloid Leukemia With Normal Cytogenetics (CN-AML): Outcome, Risk Factors and Role Of Molecular Subgroups In 752 Patients â€” A Report From The Acute Leukemia Working Party Of EBMT. Blood, 2013, 122, 921-921.	1.4	0
518	Mobilized Peripheral Blood Stem Cells Compared with Bone Marrow as the Stem Cell Source for Unrelated Donor Allogeneic Transplantation with Reduced-Intensity Conditioning in Patients with Acute Myeloid Leukemia in Complete Remission: An Analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1422-1429.	2.0	49
519	Intratumoral Heterogeneity in the Selfâ€”Renewal and Tumorigenic Differentiation of Ovarian Cancer. Stem Cells, 2012, 30, 415-424.	3.2	32
520	Mobilized peripheral blood stem cells compared with bone marrow from <scp>HLA</scp>-identical siblings for reducedâ€”intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the <scp>A</scp>cute Leukemia <scp>W</scp>orking <scp>P</scp>arty of <scp>EBMT</scp>. European Journal of Haematology, 2012, 89, 206-213.	2.2	20
521	Nilotinib Exhibits an in Vitro Antiviral Activity Against Human Cytomegalovirus (HCMV): Potential Clinical Applications. Blood, 2012, 120, 4666-4666.	1.4	2
522	Salvage Therapy with the Combination of ARA-C and Gemtuzumab Ozogamicin in Post-Allo-SCT High Risk AML Patients Is Feasible and Results in Modest Responses.. Blood, 2012, 120, 2629-2629.	1.4	0

#	ARTICLE	IF	CITATIONS
523	Significance of Busulfan Dose Intensity On Outcomes of Hematopoietic Cell Allografting for AML in Second Complete Remission or Beyond: A Report From the EBMT Acute Leukemia Working Party. <i>Blood</i> , 2012, 120, 1929-1929.	1.4	0
524	Assessment of the Effect of Nilotinib (Tasigna) Maintenance Therapy After Allogeneic Stem Cell Transplantation in Patients with Advanced CML and Ph+ ALL On Immune Reconstitution and Lymphocyte Function. <i>Blood</i> , 2012, 120, 4478-4478.	1.4	0
525	A Sensitive Replicate RQ-PCR of BCR ABL Transcripts Suggests That A Large Portion of Long Term Post Allogeneic SCT CML Patients Are in Deep MR and May Therefore Be Cured From Their Disease. <i>Blood</i> , 2012, 120, 1690-1690.	1.4	0
526	Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML in Vitro and in Vivo. <i>Blood</i> , 2012, 120, 3735-3735.	1.4	0
527	Treatment of Relapsed AML and MDS After Allogeneic Stem Cell Transplantation: A Second Transplant From a Different Donor May Be the Most Effective Option. <i>Blood</i> , 2012, 120, 1963-1963.	1.4	0
528	Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 369-379.	1.7	49
529	Linearity and Stability of Intravenous Busulfan Pharmacokinetics and the Role of Glutathione in Busulfan Elimination. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 117-123.	2.0	59
530	Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study. <i>Blood</i> , 2011, 118, 3069-3069.	1.4	11
531	Nicotinamide, a Form of Vitamin B3, Promotes Expansion of Natural Killer Cells That Display Increased In Vivo Survival and Cytotoxic Activity,. <i>Blood</i> , 2011, 118, 4035-4035.	1.4	12
532	Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial. <i>Blood</i> , 2011, 118, 480-480.	1.4	21
533	Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years,. <i>Blood</i> , 2011, 118, 3766-3766.	1.4	0
534	Long-Term Survival and Quality of Life Assessment After Allogeneic Stem-Cell Transplantation; Comparable Results Following Myeloablative and Reduced-Intensity Conditioning,. <i>Blood</i> , 2011, 118, 4096-4096.	1.4	0
535	CXCR4 Promotes the Tumorigenicity of Multiple Myeloma, Including Increased Motility, Clonogenicity, up-Regulation of VLA-4, Protection From Chemotherapy and Aggressive Tumor Development In Vivo. <i>Blood</i> , 2011, 118, 1801-1801.	1.4	11
536	Clofarabine Containing Conditioning Regimen for Allo-SCT in AML/ALL Patients: A Survey From the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2011, 118, 3004-3004.	1.4	0
537	A Randomized Controlled Multicenter Study Comparing Recombinant Interleukin 2 (rIL-2) in Conjunction With Recombinant Interferon Alpha (IFN- $\alpha$ ) Versus no Immunotherapy for Patients With Malignant Lymphoma Postautologous Stem Cell Transplantation. <i>Journal of Immunotherapy</i> , 2010, 33, 326-333.	2.4	15
538	The aberrant asynchronous replication "characterizing lymphocytes of cancer patients" is erased following stem cell transplantation. <i>BMC Cancer</i> , 2010, 10, 230.	2.6	9
539	Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma. <i>Cancer</i> , 2010, 116, 3621-3630.	4.1	44
540	Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. <i>British Journal of Haematology</i> , 2010, 148, 323-331.	2.5	55



#	ARTICLE	IF	CITATIONS
541	Immunotherapy for B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 7-9.	1.3	0
542	Introduction: advances and promise in human umbilical cord blood. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 169-170.	1.7	0
543	BKT140 Is a Novel CXCR4 Antagonist with Stem Cell Mobilization and Antimyeloma Effects: An Open-Label First Human Trial In Patients with Multiple Myeloma Undergoing Stem Cell Mobilization for Autologous Transplantation. <i>Blood</i> , 2010, 116, 2260-2260.	1.4	10
544	Adaptor Protein LNK Binds to and Is Phosphorylated by JAK3 and May Serve as a Scaffold for JAK3 Autophosphorylation In the Absence of An Appropriate Cytokine Receptor. <i>Blood</i> , 2010, 116, 2785-2785.	1.4	3
545	Fludarabine and Treosulfan Conditioning for Allogeneic Stem-Cell Transplantation; a Dose- Intense Regimen with Limited Toxicity.. <i>Blood</i> , 2010, 116, 3473-3473.	1.4	4
546	Matched Unrelated Donor Transplantation Is Curative In Selected Patients with Diffuse Large B Cell Lymphoma: A Report of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2010, 116, 363-363.	1.4	1
547	Ex Vivo Generated Donor Central Memory CD8 T Cells, Previously Shown to Enhance Engraftment of Allogeneic Bone Marrow, Also Exhibit Significant GVL Activity without Causing Gvhd In An In Vivo b Cell Lymphoma Model. <i>Blood</i> , 2010, 116, 424-424.	1.4	4
548	Halofuginone Induces Post-Transcriptional Down-Regulation of Cyclin D1, Cell Cycle Arrest and Apoptosis In Mantle Cell Lymphoma Cells through Activation of Integrated Stress Response Pathways. <i>Blood</i> , 2010, 116, 773-773.	1.4	2
549	The Impact of Center Experience on Results of Reduced Intensity “ Allogeneic Hematopoietic Stem Cell Transplantation. A Survey From the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2010, 116, 3517-3517.	1.4	6
550	Donor Lymphocyte Infusions and Second Transplantation as Salvage Treatment for Relapsed Myelofibrosis After Reduced-Intensity allografting.. <i>Blood</i> , 2010, 116, 1300-1300.	1.4	0
551	A Multi-Center Prospective Randomized Study Comparing Ibritumomab Tiuxetan (Zevalin) and High-Dose BEAM Chemotherapy (Z-BEAM) Vs. BEAM Alone as the Conditioning Regimen Prior to Autologous Stem-Cell Transplantation In Patients with Aggressive Lymphoma; Possible Advantage for Z-BEAM In Low-Risk Patients. <i>Blood</i> , 2010, 116, 686-686.	1.4	2
552	Older Patients with Normal Cytogenetics AML Have a Higher Rate of Genomic Changes Compared to Young Patients as Determined by SNP Chip Analysis. <i>Blood</i> , 2010, 116, 2479-2479.	1.4	0
553	Cyclosporine and Methotrexate Compared with Cyclosporine and Mycophenolate Mofetil as GVHD Prevention Regimens In Allogeneic Stem-Cell Transplantation From Unrelated Donors; Relative Outcomes Are Dependant on Disease Status at Transplantation. <i>Blood</i> , 2010, 116, 2314-2314.	1.4	0
554	Analysis of the Crosstalk Between TGF- $\beta$ and VEGF-Angiogenesis in an In Vivo Model of Acute Promyelocytic Leukemia. <i>Blood</i> , 2010, 116, 1845-1845.	1.4	0
555	Cig-FISH-Analysis of Extramedullary Myeloma Manifestations Shows Similar Incidence of Prognostic Genetic Aberrations Compared to Bone Manifestations or Soft Tissue Involvement. <i>Blood</i> , 2010, 116, 4993-4993.	1.4	0
556	Allogeneic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia After Prior Treatment with Nilotinib or Dasatinib. <i>Blood</i> , 2010, 116, 2348-2348.	1.4	1
557	Second Allogeneic Stem Cell Transplantation (allo-SCT) Using Reduced-Intensity Conditioning (RIC) for Acute Myeloid Leukemia (AML) Patients Who Relapsed Following a First RIC Allo-SCT: a Survey From the Acute Leukemia Working Party of EBMT.. <i>Blood</i> , 2010, 116, 3447-3447.	1.4	0
558	Attempt to Discontinue Imatinib Following Interferon Alfa Pre-Treatment In Chronic Phase CML Patients Achieving Stable Complete Cytogenetic Responses (CCyR). <i>Blood</i> , 2010, 116, 4898-4898.	1.4	0



#	ARTICLE	IF	CITATIONS
559	Combining the Ras Inhibitor Salirasib and Proteasome Inhibitors: A Potential Treatment for Multiple Myeloma. <i>Blood</i> , 2010, 116, 1810-1810.	1.4	0
560	Recent Developments in Human Umbilical Cord Blood Transplantation in Israel. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 99-103.	2.0	1
561	Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2009, 114, 5264-5270.	1.4	366
562	Comparison of Outcomes After Allogeneic HSCT for Adult Patients with AML in Remission Using in the Conditioning Regimen Either I.V. Busulfex (BU) Plus Cyclophosphamide (Cy) or TBI Plus Cy: An-ALWP-EBMT Survey.. <i>Blood</i> , 2009, 114, 195-195.	1.4	2
563	Allogeneic Hematopoietic Stem-Cell Transplantation with Reduced-Intensity Conditioning in Patients with Refractory and Relapsing Multiple Myeloma: Long-Term Follow-up.. <i>Blood</i> , 2009, 114, 3359-3359.	1.4	2
564	Prior Response to Imatinib Predicts Response to Second Line Treatment with Nilotinib in CML Patients Resistant or Intolerant to Imatinib.. <i>Blood</i> , 2009, 114, 3297-3297.	1.4	0
565	Prevalence and Prognostic Impact of Allelic Imbalances Associated with Leukemic Transformation of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.. <i>Blood</i> , 2009, 114, 1280-1280.	1.4	0
566	A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. <i>Blood</i> , 2008, 112, 3574-3581.	1.4	261
567	Umbilical Cord Blood Cells for Cardiac Repair. , 2008, , 59-72.		0
568	Interest of Non-Myeloablative Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma: A Multicenter Retrospective Study.. <i>Blood</i> , 2008, 112, 1965-1965.	1.4	1
569	Improvement of Oxidative Stress Parameters in MDS Patients with Iron Overload Treated with Deferasirox. <i>Blood</i> , 2008, 112, 2675-2675.	1.4	14
570	Reduced Intensity Versus Conventional Myeloablative Conditioning (RIC vs. MAC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Lymphoblastic Leukemia (ALL): A Survey from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2008, 112, 793-793.	1.4	4
571	Outcome after Allogeneic Stem Cell Transplantation for Adult Acute Myeloid Leukaemia Patients Exhibiting Isolated or Associated Trisomy 8 Chromosomal Abnormality: A Survey on Behalf of the Acute Leukemia Working Party (ALWP) of the EBMT.. <i>Blood</i> , 2008, 112, 1129-1129.	1.4	4
572	Two Distinct Populations of Enriched Non Mobilized Peripheral Blood Mononuclear Cells (PBMNCs) with Different Functional Capacities. <i>Blood</i> , 2008, 112, 5402-5402.	1.4	0
573	Experimental Double Cord Blood Transplantation (DCBT) of An Expanded Unit Together with a Non-Manipulated Unit in NOD/SCID Mice.. <i>Blood</i> , 2008, 112, 2313-2313.	1.4	0
574	Somatic Expansion of the Frataxin Gene GAA Repeats in MDS Patients.. <i>Blood</i> , 2008, 112, 1642-1642.	1.4	0
575	P-Glycoprotein (Pgp) - Dependent Drug Resistance to Imatinib at CML-BC Is Exclusively Developed in Aggressive Minor Blast Subpopulation (MS) and Can Be Reversed by Pgp Modulators. <i>Blood</i> , 2008, 112, 721-721.	1.4	3
576	Effect of Halofuginone, a Collagen $\pm 1(I)$ Inhibitor, on Wound Healing in Normal and Irradiated Skin: Implication for Hematopoietic Stem Cell Transplantation. <i>Acta Haematologica</i> , 2007, 118, 77-83.	1.4	13

#	ARTICLE	IF	CITATIONS
577	Fludarabine and treosulfan: A novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2007, 48, 2352-2359.	1.3	50
578	Combination of Rituximab with Initial Chemotherapy Improves Outcome of Primary Mediastinal B-Cell Lymphoma: A Retrospective Analysis of a Single Institution Cohort. <i>Blood</i> , 2007, 110, 1283-1283.	1.4	6
579	Human Placental Derived Mesenchymal Stromal Cells (MSC) Grown in 3D-Culture (PLX-I), Promotes Engraftment of Human Umbilical Cord Blood (hUCB) Derived CD34+ Cells in NOD/SCID Mice.. <i>Blood</i> , 2007, 110, 1416-1416.	1.4	2
580	Combined escBEACOPP-ABVD Therapy for Advanced Hodgkin's Lymphoma Patients with High IPS Score: An Effective Regimen and Low Positive Predictive Value of Early FDG-PET/CT Scan.. <i>Blood</i> , 2007, 110, 2319-2319.	1.4	3
581	A Prospective Study of Imatinib 400 mg vs 800 mg Frontline in High Risk Ph+ Chronic Myeloid Leukemia (CML) Patients.. <i>Blood</i> , 2007, 110, 26-26.	1.4	4
582	Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib ± Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma.. <i>Blood</i> , 2007, 110, 2735-2735.	1.4	1
583	Halofuginone Exerts Antiproliferative and Antiangiogenic Actions on Acute Promyelocytic Leukemia Cells through Modulation of the TGF $\beta$ 2 Pathway.. <i>Blood</i> , 2007, 110, 2850-2850.	1.4	1
584	The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure.. <i>Blood</i> , 2007, 110, 410-410.	1.4	6
585	A Phase I Study of INNO-406 in Patients with Advanced Philadelphia (Ph+) Chromosome-Positive Leukemias Who Are Resistant or Intolerant to Imatinib and Second Generation Tyrosine Kinase Inhibitors.. <i>Blood</i> , 2007, 110, 469-469.	1.4	12
586	LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma in the Pre- and Post-Rituximab Treatment Eras.. <i>Blood</i> , 2007, 110, 52-52.	1.4	2
587	Prognostic Significance of VEGF, VEGF Receptors, and Microvessel Density in Diffuse Large B Cell Lymphoma Treated with Anthracycline-Based Chemotherapy.. <i>Blood</i> , 2007, 110, 53-53.	1.4	3
588	Dose-Reduced Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis. Results from a Multicenter Prospective Trial of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).. <i>Blood</i> , 2007, 110, 683-683.	1.4	14
589	3D Grown Human Placental-Derived Mesenchymal Stromal Cells (PLX-I) Support and Potentiate the Engraftment of Human Cord Blood Unfractionated (UFCBC) and Fractionated CD34+ Cells (hCD34+) in Irradiated NOD/SCID Mice.. <i>Blood</i> , 2007, 110, 4104-4104.	1.4	0
590	Relapse of Acute Myeloid Leukemia after Allogeneic Stem-Cell Transplantation (SCT) with Myeloablative Conditioning Is Associated with Longer Survival Than Relapse after Reduced-Intensity Conditioning (RIC).. <i>Blood</i> , 2007, 110, 1650-1650.	1.4	0
591	Transformation to Myelofibrosis and Blastic Transformation of PV Are Associated with Higher JAK2 Mutation Levels.. <i>Blood</i> , 2007, 110, 1555-1555.	1.4	0
592	Effect of Disease Stage and Time Since Diagnosis on Time to Progression for Pegylated Liposomal Doxorubicin + Bortezomib vs Bortezomib Alone in Relapsed or Refractory Multiple Myeloma.. <i>Blood</i> , 2007, 110, 2740-2740.	1.4	1
593	High Response Rate and Improved Graft-Versus-Host Disease (GVHD) Following Bortezomib as Salvage Therapy after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation (RIC allo-SCT) for Multiple Myeloma (MM).. <i>Blood</i> , 2007, 110, 1080-1080.	1.4	3
594	Reduced-Intensity Conditioning Is Associated with Shorter Duration of Chronic GVHD Than Myeloablative Conditioning and Provides Very Good Quality of Life for Long-Term Survivors after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 1668-1668.	1.4	0

#	ARTICLE	IF	CITATIONS
595	Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation (SCT) with Fludarabine and Intravenous Busulfan Is Associated with Improved Toxicity Profile and Longer Survival Than Conditioning with Fludarabine and Melphalan in Patients with Chemo-Sensitive Hematological Malignancies.. Blood, 2007, 110, 2002-2002.	1.4	0
596	MT1-MMP and RECK Inversely Regulate Hematopoietic Progenitor Cell Egress.. Blood, 2007, 110, 1259-1259.	1.4	0
597	Low Levels of Circulating CS1, a Newly Identified Multiple Myeloma (MM) Antigen for a Novel Humanized HuLuc63 Monoclonal Antibody, Is Detected in MM Patient Sera and Correlates with Active Disease.. Blood, 2007, 110, 1509-1509.	1.4	1
598	Nicotinamide Modulates Ex-Vivo Expansion of Cord Blood Derived CD34+ Cells Cultured with Cytokines and Promotes Their Homing and Engraftment in SCID Mice.. Blood, 2006, 108, 725-725.	1.4	7
599	Imatinib High Dose (800 mg): Results of a Phase II Trial of the GIMEMA (Gruppo Italiano Malattie Tj ETQq1 1 0.784314 rgBT /Overloc Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.. Blood, 2006, 108, 4776-4776.	1.4	3
600	No Evidence for Increased Transplant Related Complications in Ph+ Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia with Prior Treatment with Dasatinib.. Blood, 2006, 108, 2975-2975.	1.4	0
601	Towards Stopping Imatinib Therapy under the Umbrella of Interferone: Alpha-Interferone Improves Molecular Response in CML Patients with Imatinib Induced Complete Cytogenetic Remission: An Early Observation from a Study of Pegylated Interferone in the Set up of Minimal Residual Disease.. Blood, 2006, 108, 4788-4788.	1.4	0
602	Expansion of Hematopoietic Stem Cells (HSC) from Cord-Blood (CB) Derived Mononuclear Cells (MNC) in Cytokine-Free Environment Using Mesenchymal Cells Spatial Co-Culture System.. Blood, 2006, 108, 2565-2565.	1.4	0
603	Comparison between Two Reduced-Intensity Conditioning Regimens Prior to Allogeneic Stem Cell Transplantation: Fludarabine and Melphalan Is Associated with Higher Incidence of Acute Graft-Versus-Host Disease and Non-Relapse Mortality and Lower Incidence of Relapse Than Fludarabine and Busulfan.. Blood, 2006, 108, 2947-2947.	1.4	0
604	No Adverse Impact of 13q14 and P53 Deletion, t(4;14)(p16;q32) or Overrepresentation of CMYC(8q24) as Detected by Fluorescence In Situ Hybridization on Outcome in Patients with Multiple Myeloma Following Dose-Reduced Allogeneic Stem Cell Transplantation.. Blood, 2006, 108, 5038-5038.	1.4	0
605	Malignant Progression of Human CML Clone Demonstrates a Unique Developmental Pathway Characterized by Altered Expression Pattern of Cancer, Adhesion and Drug Resistance Genes.. Blood, 2006, 108, 4293-4293.	1.4	0
606	Functional CXCR4 Expressing Microparticles and SDF-1 Correlate with Circulating AML Cell Counts.. Blood, 2006, 108, 4375-4375.	1.4	0
607	The Oncoprotein LMO2 Is Expressed in a Germinal Center B-Cell-Associated Pattern and Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma.. Blood, 2006, 108, 810-810.	1.4	0
608	Near-Tetraploidy Can Mask the Presence of Chromosome 13q Deletions in Plasma Cells of Patients with Multiple Myeloma.. Blood, 2006, 108, 4280-4280.	1.4	0
609	Donor C3435T Polymorphism in the Multidrug Resistance 1 (MDR1) Gene Is Associated with the Incidence of Acute and Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2006, 108, 2868-2868.	1.4	0
610	Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood, 2005, 105, 4532-4539.	1.4	228
611	Allogeneic Hematopoietic Stem-Cell Transplantation in AML and MDS Using Myeloablative Versus Reduced Intensity Conditioning: The Role of Dose-Intensity.. Blood, 2005, 106, 47-47.	1.4	2
612	Ibritumomab Tiuxetan (Zevalin) in the Conditioning Regimen for Autologous and Reduced-Intensity Allogeneic Stem-Cell Transplantation in Patients with Chemo-Refractory Non-Hodgkinâ€™s Lymphoma.. Blood, 2005, 106, 1131-1131.	1.4	2

#	ARTICLE	IF	CITATIONS
613	Persistent Mixed Chimerism in Plasma Cells Following Allogeneic Stem-Cell Transplantation in Patients with Acute Leukemia Is a Surrogate Marker for Leukemia Relapse.. Blood, 2005, 106, 2749-2749.	1.4	0
614	Spontaneous Pregnancy and Fertility Preservation Program in Women Undergoing High Dose Chemotherapy for Hematological Malignancies.. Blood, 2005, 106, 1114-1114.	1.4	0
615	Down-Regulation of Activin A by Lymphoma: A Possible Mechanism of Bone Marrow Involvement.. Blood, 2005, 106, 4669-4669.	1.4	0
616	Imatinib 800 mg: Preliminary Results of a Phase II Trial of the GIMEMA CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.. Blood, 2005, 106, 1098-1098.	1.4	4
617	Outcomes after HLA-Identical Sibling Allogeneic Peripheral Blood Stem Cell Transplantation Using Reduced Intensity Conditioning Compared to Autologous Peripheral Blood Stem Cell Transplantation for Elderly Patients with De Novo Acute Myeloid Leukemia.. Blood, 2005, 106, 43-43.	1.4	2
618	Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Experimental Hematology, 2004, 32, 122-130.	0.4	91
619	Membrane Type 1-Matrix Metalloproteinase Is Directly Involved in G-CSF Induced Human Hematopoietic Stem and Progenitor Cell Mobilization.. Blood, 2004, 104, 2675-2675.	1.4	7
620	Glucocerebroside Alleviates Chronic Graft-Versus-Host-Disease in a Murine Model.. Blood, 2004, 104, 4965-4965.	1.4	0
621	CD45 Phosphatase Is Involved in Motility and Development of Hematopoietic Stem and Maturing Cells by the Regulation of Cell Adhesion and Cytokine Signaling.. Blood, 2004, 104, 119-119.	1.4	3
622	Cell Cycle Progression and Self-Renewal Divisions of Cord Blood Derived CD34+ Cells Treated with the Polyamine Copper-Chelator Tetraethylenepentamine.. Blood, 2004, 104, 4237-4237.	1.4	0
623	Motility, Proliferation and Egress of Human AML Cells in Transplanted NOD/SCID Mice Are Regulated by Membrane Bound and Secreted Elastase.. Blood, 2004, 104, 3379-3379.	1.4	0
624	A Pilot Study of Combined Escalated BEACOPP-ABVD Therapy for Advanced Hodgkin's Lymphoma Patients with High IPS Score: The Israel Cooperative Lymphoma Group.. Blood, 2004, 104, 4576-4576.	1.4	0
625	Comparison between Anti-Thymocyte Globulin and Alemtuzumab and the Possible Impact of KIR-Ligand Mismatch in Melphalan/Fludarabine Dose-Reduced Conditioning Followed by HLA-Matched and Mismatched Unrelated Stem Cell Transplantation in Patients with Multiple Myeloma.. Blood, 2004, 104, 980-980.	1.4	0
626	Abdominal CT in the Clinical Evaluation of Acute Graft-Versus-Host Disease of the Gastrointestinal Tract: Diffuse Small Intestine Involvement Is Associated with Severity and Outcome.. Blood, 2004, 104, 5073-5073.	1.4	0
627	Ex-Vivo Expanded Human Bone Marrow-Derived AC133+ Cells To Treat Myocardial Infarction.. Blood, 2004, 104, 154-154.	1.4	0
628	Nicotinamide, a Potent SIRT2 Inhibitor, Delays Differentiation of Hematopoietic Progenitor Cells.. Blood, 2004, 104, 4142-4142.	1.4	3
629	Low Dose Thalidomide and Donor Lymphocyte Infusion as Adoptive Immunotherapy after Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma.. Blood, 2004, 104, 1646-1646.	1.4	0
630	Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood, 2002, 100, 3919-3924.	1.4	178

#	ARTICLE	IF	CITATIONS
631	Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 0, . .	2.4	1